Could a single blood thinner after stents be safer?

NCT ID NCT06916520

Recruiting now Disease control Sponsor: J.P.S Henriques Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a reduced dose of the blood thinner prasugrel (5 mg), taken alone without aspirin, is safe and effective for patients who have had a stent placed for heart disease. Researchers will compare this approach to standard dual antiplatelet therapy (aspirin plus another blood thinner). The goal is to see if the single-drug strategy reduces bleeding complications while still preventing heart attacks, strokes, and other serious events. The trial plans to enroll 300 patients and follow them for 6 to 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prasugrel 5 mg
What this could lead to: If successful, this could show that a lower dose of prasugrel alone is a safe and effective option after stent placement, reducing bleeding risk while still preventing heart attacks and strokes.
What could go wrong: This is a small, single-center Phase 4 trial, so results may not apply to all patients. The lower dose might not prevent clotting events as well as standard dual therapy, and bleeding risks remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERIAL DISEASE (CAD) PERCUTANEOUS CORONARY INTERVENTION (PCI)

Contacts and locations

Locations

Amsterdam UMC
RECRUITING

Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.